PercuSurge Targets SVG Distal Protection, Carotid Market With GuardWire
This article was originally published in The Gray Sheet
Executive SummaryPercuSurge is hoping that its GuardWire system will create a new market for distal protection from embolization in the over 500,000 stenting procedures and carotid endarectomies performed annually. The product is intended to be used in conjunction with stenting procedures in aging saphenous vein grafts and carotid arteries.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.